Loading…
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $41M | $-10M | $-17M | $-10M | -25.1% | 7.4% | - |
| 2024 | $38M | $-20M | $-27M | $-14M | -32.5% | 2.9% | - |
| 2023 | $37M | $-31M | $-37M | $-27M | -40.9% | -11.4% | - |
| 2022 | $41M | $-26M | $-47M | $-56M | -47.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 41.42 | 36.68 | 37.74 | 40.52 |
| Cost Of Revenue | 23.94 | 26.39 | 30.51 | 27.08 |
| Gross Profit | 17.48 | 10.30 | 7.23 | 13.44 |
| Operating Expense | 46.33 | 41.49 | 33.38 | 30.42 |
| Operating Income | -28.86 | -31.20 | -26.15 | -16.98 |
| EBITDA | -25.69 | -30.59 | -19.57 | -10.15 |
| EBIT | -28.86 | -36.24 | -26.15 | -16.49 |
| Pretax Income | -49.39 | -37.08 | -26.83 | -17.20 |
| Tax Provision | -1.92 | -0.30 | -0.09 | 0.06 |
| Net Income | -47.47 | -36.78 | -26.75 | -17.26 |
| Net Income Common Stockholders | -47.47 | -36.78 | -26.75 | -17.26 |
| Total Expenses | 70.28 | 67.88 | 63.89 | 57.50 |
| Interest Expense | 0 | 0.83 | 0.69 | 0.71 |
| Research And Development | 7.74 | 5.57 | 2.76 | 2.20 |
| Selling General And Administration | 37.45 | 34.78 | 29.47 | 27.07 |
| Normalized EBITDA | -4.89 | -25.40 | -19.57 | -10.63 |
| Normalized Income | -27.48 | -31.63 | -26.75 | -17.64 |
| Basic EPS | -1.69 | -1.16 | -0.57 | 0 |
| Diluted EPS | -1.69 | -1.16 | -0.57 | 0 |
| Tax Effect Of Unusual Items | -0.81 | -0.04 | 0 | 0.10 |
| Tax Rate For Calcs | 0.04 | 0.01 | 0 | 0.21 |
| Total Unusual Items | -20.80 | -5.19 | 0 | 0.48 |
| Total Unusual Items Excluding Goodwill | -20.80 | -5.19 | 0 | 0.48 |
| Net Income From Continuing Operation Net Minority Interest | -47.47 | -36.78 | -26.75 | -17.26 |
| Reconciled Depreciation | 3.17 | 5.66 | 6.58 | 6.34 |
| Reconciled Cost Of Revenue | 21.93 | 21.88 | 25.08 | 21.89 |
| Net Interest Income | 0.21 | -0.83 | -0.69 | -0.71 |
| Net Income From Continuing And Discontinued Operation | -47.47 | -36.78 | -26.75 | -17.26 |
| Total Operating Income As Reported | -49.66 | -35.56 | -26.15 | -16.98 |
| Diluted Average Shares | 28.08 | 31.82 | 46.75 | 0 |
| Basic Average Shares | 28.08 | 31.82 | 46.75 | 0 |
| Diluted NI Availto Com Stockholders | -47.47 | -36.78 | -26.75 | -17.26 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -47.47 | -36.78 | -26.75 | -17.26 |
| Net Income Continuous Operations | -47.47 | -36.78 | -26.75 | -17.26 |
| Other Income Expense | -20.75 | -5.05 | 0 | 0.48 |
| Other Non Operating Income Expenses | 0.06 | 0.14 | 0 | 0 |
| Special Income Charges | -20.80 | -5.19 | 0 | 0.48 |
| Other Special Charges | 0 | 0.82 | 0 | -0.48 |
| Impairment Of Capital Assets | 20.80 | 4.36 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.21 | -0.83 | -0.69 | -0.71 |
| Total Other Finance Cost | -0.21 | 0.83 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0.83 | 0.69 | 0.71 |
| Depreciation Amortization Depletion Income Statement | 1.15 | 1.15 | 1.15 | 1.15 |
| Depreciation And Amortization In Income Statement | 1.15 | 1.15 | 1.15 | 1.15 |
| Amortization | 1.15 | 1.15 | 1.15 | 1.15 |
| Amortization Of Intangibles Income Statement | 1.15 | 1.15 | 1.15 | 1.15 |
| Selling And Marketing Expense | 9.15 | 9.33 | 6.32 | 6.75 |
| General And Administrative Expense | 28.30 | 25.45 | 23.15 | 20.32 |
| Other Gand A | 28.30 | 25.45 | 23.15 | 20.32 |
| Operating Revenue | 41.42 | 36.68 | 35.98 | 38.69 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alpha Teknova, Inc.this co. | TKNO | $173M | - | 2.52 | -25.1% | -17.76 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 | -135.6% | -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M | - |
| 0.65 |
| -50.6% |
| 0.32 |
| Protalix BioTherapeutics, Inc. | PLX | $171M | - | 3.53 | -13.7% | -36.89 |
| Sanara MedTech Inc. | SMTI | $167M | - | 27.41 | -633.5% | 16.81 |
| Journey Medical Corporation | DERM | $166M | - | 4.26 | -35.9% | -35.25 |
| Anika Therapeutics, Inc. | ANIK | $165M | - | 1.20 | -7.6% | -31.67 |
| Peer Median | - | - | 3.90 | -43.2% | -6.28 | |